Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3) (AEGIS)

17 novembre 2026 aggiornato da: Yu Zhang, Xiangya Hospital of Central South University

An Exploratory Clinical Study of APL-1702 (Drug-Device Combination) Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)

This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

159

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Hunan
      • Changsha, Hunan, Cina, 410008
        • Reclutamento
        • Xiangya Hospital of Central South University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  1. Voluntary participation in this study, understanding of the study procedures, and ability to provide written informed consent;
  2. Part 1 Age ≥18 years; Part 2 Age≥18 years and≤45 years
  3. CIN histology: Part 1, hrHPV-positive and histologically confirmed CIN2 within 3 months before the first treatment; Part 2, hrHPV-positive and histologically confirmed CIN3 within 3 months before the first treatment, with the lesion involving 50% or less of the cervical area. Histological eligibility is confirmed by the central laboratory.
  4. Adequate colposcopic examination, with the entire cervical transformation zone and squamocolumnar junction visible and the entire lesion margin visible.
  5. A strong desire to preserve cervical structure and/or function, and the investigator considers non-surgical treatment acceptable.
  6. The investigator considers the cervical size suitable for placement of the APL-1702 device
  7. Negative pregnancy test; no pregnancy planned from study initiation until 3 months after the last treatment or 24 weeks after the first treatment, whichever is later. Participants must have abstained from sexual activity or used effective contraception from the end of the last menstrual period to study entry and must agree to use condoms during the protocol-defined contraceptive period.

Exclusion Criteria:

  1. Cervical adenocarcinoma in situ (AIS), other glandular epithelial lesions, invasive cervical cancer, or suspected malignant lesions.
  2. Lesions extending to the vaginal wall, endocervical canal, vaginal fornix, or vulvar region.
  3. Previous physical or surgical treatment of the cervix resulting in incomplete cervical structure (for example, cold knife conization), or physical or surgical treatment for CIN2 or CIN3 after the current histopathological diagnosis.
  4. The first study treatment occurs within 7 half-lives after the last dose of an antiviral medication.
  5. History of toxic shock syndrome.
  6. Severe pelvic inflammatory disease, severe cervicitis, or other serious gynecological infections identified by colposcopy or clinical examination.
  7. The investigator considers that vaginal bleeding during treatment may affect treatment efficacy.
  8. Administration of any inactivated vaccine within 2 weeks before study treatment or any live vaccine within 4 weeks before study treatment.
  9. Unresolved severe cardiovascular, neurological, psychiatric, endocrine, or hematologic diseases; known severe immunodeficiency; need for long-term glucocorticoids or immunosuppressive therapy; or a history of malignancy within 5 years.
  10. Clinically significant immunosuppression, confirmed autoimmune disease, or primary immunodeficiency.
  11. Known or screening-detected active sexually transmitted diseases (STDs), including but not limited to HIV infection, syphilis, or genital herpes, unless adequately treated with negative results before study treatment.
  12. Presence of a cardiac pacemaker.
  13. Suspected or known porphyria, or known allergy to the study drug or chemically related compounds.
  14. Allergy to silicone.
  15. Pregnant or breastfeeding.
  16. Childbirth or miscarriage within 6 weeks before enrollment.
  17. Participation in another clinical trial within 30 days before study treatment.
  18. Poor compliance or investigator's judgment that the subject is unsuitable for participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part 1 - Q3W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 1 - Q3W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 1 - Q2W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 1 - Q2W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 1 - Q1W x 3

Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 1 - Q1W x 6

Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Sperimentale: Part 2 - Month 0/1/3

Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q3W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q2W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 3.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed.

Regimen: Q1W x 6.

APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1: Histological regression rate at Week 24 after the first treatment
Lasso di tempo: Week 24 after the first treatment

Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

Week 24 after the first treatment
Part 2: Histological regression rate at Week 24 after the first treatment
Lasso di tempo: Week 24 after the first treatment

Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

Week 24 after the first treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1 hrHPV clearance rate
Lasso di tempo: 28 days after the final treatment course and Week 24 after the first treatment

Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

28 days after the final treatment course and Week 24 after the first treatment
Part 1 incidence and characteristics of adverse events and serious adverse events
Lasso di tempo: From informed consent through Week 96 after the first treatment

Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

From informed consent through Week 96 after the first treatment
Part 1 long-term hrHPV clearance rate
Lasso di tempo: Weeks 36, 60, and 96 after the first treatment

Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

Weeks 36, 60, and 96 after the first treatment
Part 1 long-term histological regression rate
Lasso di tempo: Weeks 36, 60, and 96 after the first treatment

Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only.

Weeks 36, 60, and 96 after the first treatment
Part 2 hrHPV clearance rate
Lasso di tempo: Week 24 after the first treatment

Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

Week 24 after the first treatment
Part 2 incidence and characteristics of adverse events and serious adverse events
Lasso di tempo: From informed consent through Week 48 after the first treatment

Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

From informed consent through Week 48 after the first treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 maggio 2025

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 luglio 2029

Date di iscrizione allo studio

Primo inviato

11 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi